RxDoctor Payments Data

Aryn Earnhardt

Nurse Practitioner · Berkeley, CANPI 1740552850

Payments from drug & device makers

$5,884in general payments, 2019–2025

Across 40 payments — averaging $147.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AbbVie$894
  • Amgen$160
  • SK Life Science, Inc.$130
  • Teva Pharmaceuticals USA, Inc.$117
  • plus $390 from 5 others

What the payments were for

  • Consulting fees$2,21438%
  • Speaking & faculty fees$1,81531%
  • Food & beverage$1,85131%
  • Education$40%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,884 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$100,080
Medicare patients
211
Services billed
6,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm80$68,872
RytaryCarbidopa/Levodopa41$38,769
LyricaPregabalin13$34,820
UbrelvyUbrogepant24$31,993
Aimovig AutoinjectorErenumab-Aooe25$26,253
ImitrexSumatriptan Succinate11$7,797
Rasagiline Mesylate24$6,771
Carbidopa-LevodopaCarbidopa/Levodopa103$4,641
Rivastigmine21$3,997
Lacosamide28$2,857
Gabapentin100$2,334
Oxcarbazepine31$2,197
Levetiracetam83$2,079
Sumatriptan Succinate94$1,959
Memantine Hcl70$1,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerLyrica$101$34,82013 claims
AbbVieUbrelvy$894$31,99324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Berkeley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →